Antibodies have become an established treatment modality in cancer therapy during the last decade. However, these treatments often suffer from an insufficient and heterogeneous response despite validated antigen or target receptor expression in the tumor. In fact, therapeutic success depends on both the presence of the tumor antigen and its accessibility by the antibody. In search of a suitable preclinical animal model to evaluate the mechanisms of tumor heterogeneity and hemodynamics, we characterized two exemplary non-Hodgkin lymphoma subtypes with comparable CD20 expression and metabolism, SUDHL-4 and Granta-519, using multimodal imaging techniques. Methods: To investigate in vivo biodistribution, two differently modified αCD20 antigen-binding fragments (Fab), prepared by PASylation with a 200-residue polypeptide tag comprising Pro, Ala, and Ser (PAS 200 ) and by fusion with an albumin-binding domain (ABD), were radiolabeled with 125 I and intravenously injected into immunocompromised mice bearing corresponding xenografts. Results: Validation with 18 F-FDG revealed a similar distribution in vital tumor tissue 1 h after injection. However, large differences in tumor uptake were observed when the CD20-specific radiotracers 125 I-Fab-ABD and 125 I-Fab-PAS 200 were applied (respective percentages injected dose per gram at 24 h after injection: 12.3 and 2.4 for Granta-519 vs. 5.8 and 1.2 for SUDHL-4). Three-dimensional light-sheet fluorescence microscopy with Cy5-Fab-PAS 200 confirmed better tracer extravasation in the Granta-519 tumors. Moreover, dynamic contrast-enhanced (DCE) MRI revealed significantly reduced perfusion in the SUDHL-4 tumors. Conclusion: Tracer uptake was highly dependent on local tumor perfusion and Fab permeation in the SUDHL-4 and Granta-519 tumors. Thus, the SUDHL-4 xenograft offers an excellent model for investigating the influence of therapies affecting tumor angiogenesis.
Purpose: Last year we have shown that 18F-FLT is superior surrogate marker than 18F-FDG for very early response assessment to therapy in malignant Lymphoma. In this study, we use FLT-PET to predict the response of ewing sarcoma to different cancer therapy and investigate its relation to cancer cell death, especially apoptosis. Methods: FLT and/ or FDG PET were performed prior and early in each therapeutic course on SCID mice bearing with various tumor cells. Ewing sarcoma A673 was applied for investigation of the response to sorafenib treatment or Radiotherapy. GFP labelled Lymphoma cells (Myc449, Myc665) with or without transportation of Bcl2 gene was employed for the observation of cell death especially apoptosis after the treatment with aura kinase inhibitor or chemotherapy. Tumor-to-background ratios (TBR) of FLT-PET were compared to that of FDG-PET. PET findings were correlated with optical Imaging, histopathology and in vitro data comprising cellular tracer uptake, cell cycle related protein expression, cell cycle distribution and viability assessment. Results: In vitro study shows that sarcoma A673 cells were sensitive to all therapy. For in vivo studies, tumor volume of sorafenib treated animals showed modest increase of 0.1cm3 (range 0.02cm3 to 0.2cm3, SD=0.09) within the first week as opposed to a 15-fold increase in control mice. Median TBR of FLT-PET decreased significantly to 30.1% compared to baseline as early as 5d after therapy (range 11.3-53.5%, n=12, p=0.0004). On the other side, TBR in FDG-PET also showed the similar tendency (median TBR 74.6%, range 28.1%-131.8%, n=12, p=0.02). But the reduction of TBR in FLT was significantly stronger than that in FDG (p<0.001). In vitro study of lymphoma cells with Bcl2 transduction showed a strong anti- cell death ability, which will be served for the link between FLT PET and cell death. Conclusion: Compared with FDG-PET, FLT-PET is able to predict the response in the early therapeutic course and has a high specificity for the detection of ewing sarcoma. Continuing studies are intensively carried out to investigate FLT and FDG PET in relation to therapy-induced cell death. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4049. doi:1538-7445.AM2012-4049
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.